AZ Claims EU Okay for Imfinzi in Bladder Cancer

AZ claims EU okay for Imfinzi in bladder cancer

AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug

AstraZeneca’s Imfinzi approved in Europe for muscle-invasive bladder cancer - Pharmaceutical Technology

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Imfinzi Regimen Cuts Recurrence Risk by a Third and Boosts Two-Year Survival in Bladder Cancer

Imfinzi Regimen Cuts Recurrence Risk by a Third and Boosts Two-Year Survival in Bladder Cancer (IN BRIEF) The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) combined with gemcitabine and cisplatin as neoadjuvant therapy, followed by Imfinzi adjuvant monotherapy, for adults with resectable muscle-invasive bladder cancer. This approval is anchored in NIAGARA Phase III trial data showing a 32% reduction in the composite risk of…

TCF3 Drives Bladder Cancer via TMBIM6-Ca2+ Ferroptosis

In the relentless pursuit to decipher the molecular underpinnings of bladder cancer, a groundbreaking study has unveiled a pivotal role of the transcription factor TCF3 in orchestrating tumor progression through a novel ferroptosis-dependent pathway. Researchers led by Yang WF and colleagues have illuminated how TCF3 exacerbates bladder cancer development by modulating the TMBIM6-Ca²⁺ axis, intricately […]